Page last updated: 2024-12-05

3-chloro-2-methylprop-1-ene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID11241
CHEMBL ID157368
CHEBI ID82419
MeSH IDM0144547

Synonyms (92)

Synonym
7a9x1c3i3o ,
methyl allyl chloride [un2554] [flammable liquid]
unii-7a9x1c3i3o
chlorue de methallyle
isobutenyl chloride
3-cloro-2-metil-prop-1-ene
nsc-7303
3-chloro-2-methylpropene
3-chlor-2-methyl-prop-1-en
3-chloro-2-methyl-1-propene
2-methyl-allylchlorid
563-47-3
methallyl chloride
.beta.-methallyl chloride
2-methylallyl chloride
wln: g1y1&u1
propene, 3-chloro-2-methyl-
1-propene, 3-chloro-2-methyl-
nsc7303
cloruro di metallile
chlorure de methallyle
.beta.-methylallyl chloride
nci-c54820
.gamma.-chloroisobutylene
2-methyl-2-propenyl chloride
methylallyl chloride
3-chloro-2-methylpropene, technical grade (containing 5% dimethylvinyl chloride)
nsc 7303
3-chloro-2-methylpropene (iupac)
3-chlor-2-methyl-prop-1-en [german]
ai3-14901
un2554
chlorue de methallyle [french]
einecs 209-251-2
beta-methylallyl chloride
cloruro di metallile [italian]
brn 0878160
3-chloro-2-methylpropene, technical grade (containing 5% dimethylvinyl chloride)
hsdb 1149
2-methallyl chloride
2-methyl-allylchlorid [german]
1-chloro-2-methyl-2-propene
chlorure de methallyle [french]
beta-methallyl chloride
3-chloroisobutene
3-cloro-2-metil-prop-1-ene [italian]
gamma-chloroisobutylene
3-chloroisobutylene
ccris 869
inchi=1/c4h7cl/c1-4(2)3-5/h1,3h2,2h
3-chloro-2-methylprop-1-ene
NCGC00091790-01
3-chloro-2-methyl-1-propene, technical grade, 90%
3-chloro-2-methyl-1-propene, contains ~250 ppm pentaerythritol tetrakis(3,5-di-tert-butyl-4-hydroxyhydrocinnamate) as stabilizer, 98%
chebi:82419 ,
CHEMBL157368
AKOS000120667
A831010
3-chloranyl-2-methyl-prop-1-ene
NCGC00091790-02
C19363
dtxcid30279
cas-563-47-3
tox21_303609
NCGC00257307-01
dtxsid1020279 ,
NCGC00259189-01
tox21_201640
3-chloro-2-methylpropene contains 250 ppm pentaerythritol tetrakis(3,5-di-tert-butyl-4-hydroxyhydrocinnamate) as stabilizer
FT-0615349
.beta.-methylallylchloride
3-chloro-2-methylprop-1-ene [hsdb]
chloro-2-methylpropene, 3-
3-chloro-2-methyl-1-propene [mi]
methallylchloride
3-chloro-2-methyl-prop-1-ene
2-methyl-3-chloropropene
(2'-methylallyl) chloride
3-chloro-2-methyl-l-propene
beta-methyl-allyl chloride
3-chloro-2-methyl -1-propene
3-chloro-2-methyl-propene
3-chloro-2-methyl propene-1
3-chloro-2-methyl propene
STR02074
3-chloro-2-methylpropene-1
un 2554
mfcd00000953
J-512203
F0001-1476
Q15632849
EN300-20997

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Rats expired 30% of the administered DMVC unchanged in the 24 hr after dosing compared to only 7% of the administered CMP."( Comparative metabolism and disposition of 1-chloro- and 3-chloro-2-methylpropene in rats and mice.
Burka, LT; Ghanayem, BI,
)
0.13
" Dose-response modelling of the data for 1-chloro-2-methylpropene gave a BMDL10 for nasal carcinomas in male rats of 11 mg/kg-bw/day (after correction for the 5 days/week dosage schedule)."( Application of the margin of exposure (MoE) approach to substances in food that are genotoxic and carcinogenic - example: 1-methylcyclopropene and its impurities (1-chloro-2-methylpropene and 3-chloro-2-methylpropene).
Leblanc, JC; Renwick, A; Setzer, RW, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organochlorine compoundAn organochlorine compound is a compound containing at least one carbon-chlorine bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency3.16230.004023.8416100.0000AID485290
Chain A, HADH2 proteinHomo sapiens (human)Potency39.81070.025120.237639.8107AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency39.81070.025120.237639.8107AID893
GLI family zinc finger 3Homo sapiens (human)Potency3.43760.000714.592883.7951AID1259369
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency0.02730.001530.607315,848.9004AID1224849
estrogen nuclear receptor alphaHomo sapiens (human)Potency30.42310.000229.305416,493.5996AID743069; AID743075
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency52.78370.001019.414170.9645AID743191
lethal factor (plasmid)Bacillus anthracis str. A2012Potency2.51190.020010.786931.6228AID912
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID19825Partition coefficient (logP)1995Journal of medicinal chemistry, Feb-17, Volume: 38, Issue:4
Molecular similarity matrices and quantitative structure-activity relationships: a case study with methodological implications.
AID37563Aneuploidy activity was determined; - indicates negative induction of aneuploidy in Aspergillus nidulans1995Journal of medicinal chemistry, Feb-17, Volume: 38, Issue:4
Molecular similarity matrices and quantitative structure-activity relationships: a case study with methodological implications.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (33.33)18.7374
1990's2 (16.67)18.2507
2000's4 (33.33)29.6817
2010's2 (16.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.26

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.26 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.31 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.26)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (15.38%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (84.62%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]